Showing results (321-330 of 348) with videos related to
Sort By:
Pageof 35
FEBS Letters|December 17, 2011
Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5Suzanne R Kalb, Jakub Baudys, Robert P Webb, et al.Plos One|January 13, 2012
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism modelJean Mukherjee, Jacqueline M Tremblay, Clinton E Leysath, et al.Acta Crystallographica. Section D, Biological Crystallography|September 25, 2004
Crystallization and preliminary X-ray diffraction studies of isoform alpha1 of the human thyroid hormone receptor ligand-binding domainF M Nunes, R Aparicio, M A M Santos, et al.Bioorganic & Medicinal Chemistry Letters|January 4, 2017
A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype AWilliam A Harrell, Rebecca C Vieira, Susan M Ensel, et al.International Journal of Obesity (2005)|July 28, 2016
Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndromeC S Filgueira, E Nicolov, R L Hood, et al.Molecular Endocrinology (Baltimore, Md.)|October 17, 1998
Estrogen receptor activation function 1 works by binding p160 coactivator proteinsP Webb, P Nguyen, J Shinsako, et al.Molecular Cancer Research : MCR|March 31, 2005
Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formationChad J Creighton, Jennifer L Bromberg-White, David E Misek, et al.Oncogene|March 13, 2001
Role of direct interaction in BRCA1 inhibition of estrogen receptor activityS Fan, Y X Ma, C Wang, et al.Journal of Translational Medicine|July 3, 2013
A multi-site feasibility study for personalized medicine in canines with osteosarcomaNoel R Monks, David M Cherba, Steven G Kamerling, et al.Science (New York, N.Y.)|May 23, 1998
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factorN S Duesbery, C P Webb, S H Leppla, et al.Pageof 35